JP2018511639A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018511639A5 JP2018511639A5 JP2017554262A JP2017554262A JP2018511639A5 JP 2018511639 A5 JP2018511639 A5 JP 2018511639A5 JP 2017554262 A JP2017554262 A JP 2017554262A JP 2017554262 A JP2017554262 A JP 2017554262A JP 2018511639 A5 JP2018511639 A5 JP 2018511639A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- tyrosine
- methyl
- composition according
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 54
- NHTGHBARYWONDQ-UHFFFAOYSA-N (+-)-α-methyl-tyrosine Chemical compound OC(=O)C(N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-UHFFFAOYSA-N 0.000 claims description 26
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 25
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 15
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 10
- 239000000808 adrenergic beta-agonist Substances 0.000 claims description 10
- 238000011156 evaluation Methods 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 206010003805 Autism Diseases 0.000 claims description 6
- 208000020706 Autistic disease Diseases 0.000 claims description 6
- 230000001755 vocal effect Effects 0.000 claims description 6
- 208000036640 Asperger disease Diseases 0.000 claims description 5
- 201000006062 Asperger syndrome Diseases 0.000 claims description 5
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 5
- 208000025890 Social Communication disease Diseases 0.000 claims description 5
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 5
- 208000029560 autism spectrum disease Diseases 0.000 claims description 5
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 206010024264 Lethargy Diseases 0.000 claims description 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 4
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 4
- 208000013403 hyperactivity Diseases 0.000 claims description 4
- 229960002052 salbutamol Drugs 0.000 claims description 4
- 230000001953 sensory effect Effects 0.000 claims description 4
- 206010042008 Stereotypy Diseases 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 208000016686 tic disease Diseases 0.000 claims description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 2
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 2
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims description 2
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims description 2
- 206010000117 Abnormal behaviour Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 claims description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical group N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 2
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 229940125388 beta agonist Drugs 0.000 claims description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 2
- 229960000623 carbamazepine Drugs 0.000 claims description 2
- 229960001117 clenbuterol Drugs 0.000 claims description 2
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims description 2
- 238000004891 communication Methods 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 230000002996 emotional effect Effects 0.000 claims description 2
- 229960005139 epinephrine Drugs 0.000 claims description 2
- 229960001022 fenoterol Drugs 0.000 claims description 2
- 229960002848 formoterol Drugs 0.000 claims description 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 2
- 229960001268 isoetarine Drugs 0.000 claims description 2
- 229940039009 isoproterenol Drugs 0.000 claims description 2
- 229950008204 levosalbutamol Drugs 0.000 claims description 2
- -1 lithodrine Chemical compound 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims description 2
- 229960002657 orciprenaline Drugs 0.000 claims description 2
- 229960005414 pirbuterol Drugs 0.000 claims description 2
- 229960002288 procaterol Drugs 0.000 claims description 2
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 claims description 2
- 230000003252 repetitive effect Effects 0.000 claims description 2
- 229960004017 salmeterol Drugs 0.000 claims description 2
- 230000003997 social interaction Effects 0.000 claims description 2
- 229960000195 terbutaline Drugs 0.000 claims description 2
- 229960000604 valproic acid Drugs 0.000 claims description 2
- 206010029897 Obsessive thoughts Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000013434 obsessive interests Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/686,545 US9308188B2 (en) | 2013-10-22 | 2015-04-14 | Compositions and methods for treating intestinal hyperpermeability |
| US14/686,545 | 2015-04-14 | ||
| US15/059,602 US9763903B2 (en) | 2013-10-22 | 2016-03-03 | Compositions and methods for treating intestinal hyperpermeability |
| US15/059,602 | 2016-03-03 | ||
| PCT/US2016/024432 WO2016167944A2 (en) | 2015-04-14 | 2016-03-28 | Compositions and methods for treating intestinal hyperpermeability |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018511639A JP2018511639A (ja) | 2018-04-26 |
| JP2018511639A5 true JP2018511639A5 (https=) | 2019-05-16 |
| JP6858131B2 JP6858131B2 (ja) | 2021-04-14 |
Family
ID=57126753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017554262A Active JP6858131B2 (ja) | 2015-04-14 | 2016-03-28 | 自閉症を治療するための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP3283115B1 (https=) |
| JP (1) | JP6858131B2 (https=) |
| KR (1) | KR20180015126A (https=) |
| CN (1) | CN107835695B (https=) |
| AU (1) | AU2016247301A1 (https=) |
| BR (1) | BR112017022184A2 (https=) |
| CA (1) | CA2982442A1 (https=) |
| EA (1) | EA038339B1 (https=) |
| IL (1) | IL254963A0 (https=) |
| MX (1) | MX2017013176A (https=) |
| PH (1) | PH12017501864A1 (https=) |
| WO (1) | WO2016167944A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10813901B2 (en) | 2013-10-22 | 2020-10-27 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
| US10751313B2 (en) | 2013-10-22 | 2020-08-25 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
| WO2020018291A1 (en) * | 2018-07-19 | 2020-01-23 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
| EP3823593A4 (en) * | 2018-07-19 | 2022-04-20 | Yamo Pharmaceuticals LLC | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTISM |
| KR102726917B1 (ko) | 2019-02-01 | 2024-11-07 | 닥터레이몬드 랩(주) | 자폐증의 예측방법 |
| PH12021552866A1 (en) | 2019-05-14 | 2022-11-07 | Tyme Inc | Compositions and methods for treating cancer |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4165382A (en) * | 1977-10-17 | 1979-08-21 | Jose Pozuelo | Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine |
| AU2001251595A1 (en) * | 2000-04-13 | 2001-10-30 | William T Evans | Gaba substrate and the use thereof for treating cognitive and emotional disorders |
| CA2582346A1 (en) * | 2004-10-01 | 2006-04-13 | The Research Foundation Of State University Of New York | Morphine and morphine precursors |
| WO2012123819A1 (en) * | 2011-03-15 | 2012-09-20 | Optinose As Et Al | Nasal delivery |
| PL220308B1 (pl) * | 2011-06-03 | 2015-10-30 | Kobel Buys Krystyna | Zastosowanie klenbuterolu do leczenia objawów autyzmu dziecięcego oraz klenbuterol do zastosowania w leczeniu objawów autyzmu dziecięcego |
| JP6796372B2 (ja) * | 2012-01-03 | 2020-12-09 | キュアマーク， リミテッド ライアビリティ カンパニー | 神経障害および精神障害の行動症状を治療する方法 |
| US20130183263A1 (en) * | 2012-01-17 | 2013-07-18 | Steven Hoffman | Pharmaceutical compositions and methods |
| US9326962B2 (en) * | 2013-10-22 | 2016-05-03 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
| US20150111878A1 (en) * | 2013-10-22 | 2015-04-23 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
-
2016
- 2016-03-28 KR KR1020177032439A patent/KR20180015126A/ko not_active Withdrawn
- 2016-03-28 CN CN201680023669.XA patent/CN107835695B/zh active Active
- 2016-03-28 BR BR112017022184A patent/BR112017022184A2/pt not_active IP Right Cessation
- 2016-03-28 EA EA201792278A patent/EA038339B1/ru unknown
- 2016-03-28 MX MX2017013176A patent/MX2017013176A/es unknown
- 2016-03-28 EP EP16714718.0A patent/EP3283115B1/en active Active
- 2016-03-28 EP EP24180230.5A patent/EP4438059A3/en active Pending
- 2016-03-28 JP JP2017554262A patent/JP6858131B2/ja active Active
- 2016-03-28 WO PCT/US2016/024432 patent/WO2016167944A2/en not_active Ceased
- 2016-03-28 AU AU2016247301A patent/AU2016247301A1/en not_active Abandoned
- 2016-03-28 CA CA2982442A patent/CA2982442A1/en not_active Abandoned
-
2017
- 2017-10-10 IL IL254963A patent/IL254963A0/en unknown
- 2017-10-11 PH PH12017501864A patent/PH12017501864A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018511639A5 (https=) | ||
| Stahl et al. | SNRIs: the pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants | |
| Martinotti et al. | The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview | |
| Rowbotham et al. | Efficacy and safety of the α4β2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain | |
| Paulpandi et al. | In vitro anti-viral effect of β-santalol against influenza viral replication | |
| Conley et al. | Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: a meta-analysis | |
| Liu et al. | Equivalency of tricyclic antidepressants in open‐label neuropathic pain study | |
| JP2017519807A5 (https=) | ||
| Alorfi | Pharmacological treatments of fibromyalgia in adults; overview of phase IV clinical trials | |
| Ramzy | Comparative efficacy of newer antidepressants in combination with pregabalin for fibromyalgia syndrome: a controlled, randomized study | |
| Cruz | Xadago (Safinamide): A Monoamine oxidase B inhibitor for the adjunct treatment of motor symptoms in Parkinson’s disease | |
| Li et al. | Heme oxygenase-1 aggravates heat stress-induced neuronal injury and decreases autophagy in cerebellar Purkinje cells of rats | |
| EA201991374A1 (ru) | Водорастворимое производное эпиаллопрегнанолона и его применение | |
| JP2016510343A5 (https=) | ||
| Tzellos et al. | A2δ ligands gabapentin and pregabalin: future implications in daily clinical practice | |
| Wang et al. | Sertraline plus deanxit to treat patients with depression and anxiety in chronic somatic diseases: a randomized controlled trial | |
| Ravishankar et al. | The efficacy of atomoxetine in treating adult attention deficit hyperactivity disorder (ADHD): A meta-analysis of controlled trials | |
| Müller et al. | Aminoadamantanes: from treatment of Parkinson’s and Alzheimer’s disease to symptom amelioration of long COVID-19 syndrome? | |
| Pettorruso et al. | Amantadine in the treatment of pathological gambling: a case report | |
| JP2014513121A5 (https=) | ||
| Fallah et al. | Chloral hydrate, chloral hydrate-promethazine and chloral hydrate-hydroxyzine efficacy in electroencephalography sedation | |
| Yu et al. | Efficacy and safety of pregabalin in neuropathic pain followed spinal cord injury: a review and meta-analysis of randomized controlled trials | |
| Zaheer et al. | Trichloroethylene and Parkinson disease | |
| JP2022528566A5 (https=) | ||
| Bakker et al. | Safety and pharmacokinetics of HTL0018318, a novel M1 receptor agonist, given in combination with donepezil at steady state: a randomized trial in healthy elderly subjects |